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ABSTRACT
Introduction Gestational diabetes increases 
maternal and offspring complications in pregnancy 
and cardiovascular complications in the long term. 
The nutritional supplement myo-inositol may prevent 
gestational diabetes; however, further evaluation is 
required, especially in multiethnic high-risk mothers. Our 
pilot trial on myo-inositol to prevent gestational diabetes 
will evaluate trial processes, assess acceptability to 
mothers and obtain preliminary estimates of effect and 
cost data prior to a large full-scale trial.
Methods and analysis EMmY is a multicentre, placebo-
controlled, double-blind, pilot, randomised trial, with 
qualitative evaluation. We will recruit pregnant women at 
12–15+6 weeks’ gestation, with gestational diabetes risk 
factors, from five maternity units in England between 2018 
and 2019. We will randomise 200 women to take either 
2 g of myo-inositol powder (intervention) or placebo, twice 
daily until delivery. We will assess rates of recruitment, 
randomisation, adherence to intervention and follow-up. 
Gestational diabetes will be diagnosed at 24–28 weeks as 
per the National Institute for Health and Care Excellence 
(NICE) criteria (fasting plasma glucose: ≥5.6 mmol/L and 
2-hour plasma glucose: ≥7.8 mmol/L). We will assess the 
effects of myo-inositol on glycaemic indices at 28 weeks 
and on other maternal, fetal and neonatal outcomes at 
postnatal discharge. Qualitative evaluation will explore 
the acceptability of the trial and the intervention among 
women and healthcare professionals. Cost data and 
health-related quality of life measures will be captured. 
We will summarise feasibility outcomes using standard 
methods for proportions and other descriptive statistics, 
and where appropriate, report point estimates of effect 
sizes (eg, mean differences and relative risks) and 
associated 95% CIs.
Ethics and dissemination Ethical approval was obtained 
through the London Queen Square Research Ethics 
Committee (17/LO/1741). Study findings will be submitted 
for publication in peer-reviewed journals. Newsletters will 
be made available to participants, healthcare professionals 
and members of Katie’s Team (a patient and public 
advisory group) to disseminate.
Trial registration number ISRCTN48872100.
Protocol version and date Version 4.0, 15 January 2018.
INTRODUCTION 
Increasing rates of obesity worldwide, 
combined with sedentary lifestyle, has contrib-
uted to the rise in the number of women with 
gestational diabetes, a condition with high 
blood glucose levels diagnosed in pregnancy. 
Since 2010, the rates of gestational diabetes 
approach 24% in inner city maternity units in 
the UK.1 This is likely to be due to the multi-
ethnic populations in inner city areas with 
high levels of ‘at-risk’ populations, who are 
at greater risk of gestational diabetes, such as 
women of South Asian origin .2 
Strengths and limitations of this study
 ? Pilot study on trial processes, clinical outcomes and 
cost data to inform definitive trial.
 ? Qualitative evaluation on the acceptability of the trial 
and intervention.
 ? Pragmatically designed and reviewed by a patient 
and public involvement advisory group to allow 
for integration into current routine National Health 
Service clinical practice.
 ? Trial applicable only to women with proficiency in 
English language.
 ? Intervention available over the counter and may be 
accessible to trial participants.
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Gestational diabetes is associated with an increased 
risk of pregnancy complications including pre-eclampsia, 
macrosomia, caesarean section, postpartum haemor-
rhage, stillbirths and neonatal deaths.3 4 Therefore, preg-
nant women who are considered to be at high risk are 
offered a screening test for gestational diabetes.5 Phar-
macological interventions such as metformin have not 
been shown to prevent gestational diabetes, and lifestyle 
interventions are challenging to implement, given their 
complexity.6 Myo-inositol, a nutritional supplement, has 
been reported to have beneficial effects in preventing 
gestational diabetes in some randomised trials.6
Existing randomised trials on myo-inositol are of poor 
quality, with small sample sizes, and involve homoge-
neous populations, mainly of Caucasian mothers from 
Italy.7 The generalisability of these findings to the 
National Health Service (NHS) setting is not known. 
Given the large sample size, and resources required to 
undertake a large-scale trial on the effects of myo-inositol 
on preventing gestational diabetes and its complications, 
there is a need to pilot trial procedures,8 ensure accept-
ability to participants and healthcare professionals and 
obtain relevant preliminary data.
METHODS AND ANALYSIS
Study design
EMmY is a multicentre, randomised, placebo-con-
trolled, double-blind, pilot trial with a nested qualitative 
evaluation.
Study aim and objectives
The aim of the EMmY trial is to pilot study procedures 
and assess acceptability prior to undertaking a full-scale 
trial on myo-inositol supplementation during pregnancy 
to prevent gestational diabetes in high-risk women. Our 
primary objectives are to evaluate trial processes and 
procedures, obtain real-time data on the study design, 
assess adherence and report any side effects. Our 
secondary objectives are to assess the acceptability of 
the study and the intervention to pregnant women and 
healthcare professionals, identify reasons for non-partici-
pation and non-retention and identify barriers in recruit-
ment and standardisation of care pathways for clinicians. 
Finally, we aim to obtain preliminary estimates on the 
effects of the intervention on glycaemic status, costs and 
quality of life measures.
Study setting
The EMmY trial will be conducted in five inner city 
maternity units including Barts Health Trust (The Royal 
London Hospital, Whipps Cross University Hospital 
and Newham University Hospital), St George’s Univer-
sity Hospitals NHS Foundation Trust, and Manchester 
University Hospital NHS Foundation Trust (Manchester 
Royal Infirmary) over a period of 12 months (February 
2018–January 2019).
Study participants and eligibility criteria
Pregnant women eligible for recruitment to the EMmY 
trial are those with a singleton, viable pregnancy from 
12+0to 15+6 weeks’ gestation, able to provide written 
informed consent in English and with at least one of the 
following risk factors: family history of diabetes in any 
one of their first-degree relatives, gestational diabetes in 
a previous pregnancy, obesity (body mass index ≥30 kg/
m2), minority ethnic family origin with a high prevalence 
of diabetes (such as South Asian and Black Caribbean/
African), polycystic ovary syndrome or previous macro-
somic baby (birth weight >4.5 kg). Women on cortico-
steroids, metformin or insulin treatment are not eligible 
for recruitment. Women with known pre-existing type 
2 diabetes or diagnosed with pregestational diabetes 
in early pregnancy will not be randomised. This will be 
based on first trimester glycated haemoglobin (A1c) 
(HbA1c) levels and/or fasting and 2 hour postprandial 
oral glucose tolerance test (OGTT) depending on indi-
vidual Trust policy.
Recruitment and randomisation
All pregnant women booked for antenatal care will be 
screened against the eligibility criteria. Where possible, 
eligible participants will receive the EMmY Patient 
Information Sheet (PIS) at least 24 hours prior to their 
hospital booking visit or first trimester routine ultrasound 
scan depending on site policy. This is to make sure they 
have had ample time to consider the trial. The PIS will 
be accompanied by an invitation letter from the principal 
investigator (PI) informing patients that they may be 
approached by a member of the clinical research team, 
typically a research midwife to discuss participation in the 
trial at their hospital booking visit or first trimester ultra-
sound scan. The PIS will be discussed with eligible women 
by a member of the research team, typically a research 
midwife. Potential participants will have the opportunity 
to ask any questions and to clarify the study processes. 
If women are keen to join the study after these discus-
sions, informed written consent will be obtained. Addi-
tional consent forms will be completed prospectively with 
regards to participating in qualitative interviews and the 
collection and storage of umbilical cord blood samples 
for future research. Women who do not wish to take part 
in the research interviews or consent to cord blood collec-
tion and storage can still participate in the trial. The 
informed written consent form is submitted as supporting 
information (see online supplementary file 1).
Following consent, participants with a history of gesta-
tional diabetes will undergo an HbA1C and/or an OGTT 
test depending on individual trust policy before 16 weeks’ 
gestational age. These tests are conducted to rule out any 
potentially pre-existing but undiagnosed type 2 diabetes 
or early pregestational diabetes. Based on the National 
Institute for Health and Care Excellence (NICE) 
criteria, abnormal HbA1c results are defined as HbA1c 
levels >48 mmol/L and abnormal OGTT results defined 
as a fasting blood glucose level ≥5.6 mmol/L and/or a 
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2-hour blood glucose level ≥7.8 mmol/L post 75 g glucose 
load.5
Women with borderline HbA1c levels (41–47 mmol/L) 
at the booking visit will undergo first trimester OGTT. If 
the OGTT test shows an abnormal reading, these women 
will not be randomised. This process also allows us to 
assess the proportion of women with previous gesta-
tional diabetes, who enter subsequent pregnancies with 
potentially undiagnosed type 2 diabetes or pregesta-
tional diabetes. Participants eligible for randomisation 
will be randomly allocated to either the intervention 
group or the control group. The senior statistician 
will generate the allocation sequence. The randomisa-
tion and group allocation will be carried out through 
a secure online randomisation system. The randomi-
sation scheme will be based on permuted blocks of 
random block size (sizes 4, 6 and 8), stratified by partic-
ipating site. Research midwives will enrol and assign 
interventions to participants. Except for the senior stat-
istician, study participants, care providers, data analysts 
and outcome assessors will be blinded to the group 
allocation. The research team will be unblinded only if 
necessary for the safety of the trial participant.
Following randomisation, baseline information on 
demographic and clinical characteristics will be collected 
from participants’ maternity notes. The European 
Quality of Life 5-Dimensions 5-Level scale (EQ-5D-5L), 
a validated questionnaire, will be administered at base-
line and at the end of the trial to capture quality-adjusted 
life-years (QALYs) in all participants. Participants in the 
intervention group will be provided with the myo-inositol 
powder supplement to be taken in a dose of 2 g twice daily 
from 12+0 to 15+6 weeks’ gestational age until delivery. 
Participants in the control group will be provided with 
a placebo identical in colour, flavour and texture to the 
myo-inositol powder to be taken in the same dose and for 
the same duration of time. Information regarding supple-
ment intake and dosage will be provided to prevent misin-
terpretation of instructions or ambiguity.
Adherence to the intervention
The participants will be provided with the intervention 
or placebo packs in two stages, with half of their supply 
being provided at visit 1 (recruitment and randomisa-
tion, at 12–15+6 gestational weeks) and the remaining 
half of their supply at visit 3 (approximately 28 gestational 
weeks). A paper-based diary and/or a mobile application 
(depending on participant’s preference) will be provided 
to participants to self-report on adherence, with reminder 
features that we anticipate will encourage adherence. 
Participants will also be asked to bring any remaining 
sachets to their 28-week visit, where they will receive the 
next batch of intervention or placebo. A count of unused 
sachets (supplements) will be recorded as an additional 
measure of adherence to the intervention. Urinary 
inositol levels will also be tested at visit 3 (approximately 
28 gestational weeks) as an additional measure of adher-
ence in both groups. Text messages or phone calls will 
be made by the research team to remind participants of 
their upcoming appointments during the study. A partici-
pant will be deemed non-adherent if she has used 75% or 
less of her trial sachets. Figure 1 provides details of trial 
processes and procedures.
Sample size calculation
We expect that 1500 women will be booked for ante-
natal care each month at the participating hospitals 
and at least 300 of those will be eligible. Assuming 1000 
eligible women were approached, we expect about 25% 
(250/1000) to be consented. We expect that 20% (50) 
of women who consent to the study will have a previous 
history of gestational diabetes. These women will 
undergo an early HbA1C and/or an OGTT test before 16 
weeks’ gestational age to rule out any potentially pre-ex-
isting but undiagnosed type 2 diabetes or early preges-
tational diabetes. Any of these women with abnormal 
HbA1C (>48 mmol/L) and/or OGTT (fasting blood 
glucose ≥5.6 mmol/L and/or a 2-hour 75 g blood glucose 
level ≥7.8 mmol/L) results and hence a diagnosis of early 
gestational diabetes will be excluded from the study. This 
will result in 200 women being randomised to either the 
myo-inositol or placebo arm. With an estimated attrition 
rate of 20%, we expect that 160 (160/200) women will 
remain in the study. Among these 160 women, we expect 
80% of them (128/160) to be adherent to the study 
processes. These numbers will allow for estimation of the 
95% CIs for trial feasibility outcomes with amplitudes of 
around 10%.
Primary and secondary outcome measures and outcome 
assessment
The primary outcomes are the proportion of eligible, 
consented and randomised participants. The secondary 
outcomes include the acceptability of the study and 
the intervention as well as the proportion of outcome 
measures obtained in the trial. Laboratory outcomes will 
be assessed at 28 weeks’ gestation including plasma glucose 
levels and the diagnosis of gestational diabetes. This will 
be achieved through fasting and 2-hour postprandial 75 g 
OGTT. Gestational diabetes will be diagnosed according 
to the 2015 NICE criteria (fasting glucose ≥5.6 mmol/L, 
2 hour ≥7.8 mmol/L). Other laboratory outcomes include 
insulin levels, leptin and adiponectin levels, c-peptide 
levels at fasting and 2 hours postglucose load, (Homeo-
static Model Assessment for Insulin Resistance (HOMA-
IR) and urinary inositol levels.
Maternal, fetal and neonatal outcomes will also be 
assessed at delivery and/or discharge. Maternal outcomes 
include pre-eclampsia, gestational age at delivery, 
postpartum haemorrhage, mode of delivery, preterm 
delivery before 34 and 37 weeks, perineal trauma, 
admission to high-dependency unit or intensive care 
unit, maternal death and maternal infection. Fetal and 
neonatal outcomes include, birth weight, macrosomia 
(birth weight >4.5 kg), admission to neonatal intensive 
care unit, shoulder dystocia, neonatal death, respiratory 
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Figure 1 Trial scheme diagram on the conduct of the EMmY study. NICE, National Institute for Health and Care Excellence; 
NICU, neonatal intensive care unit; OGTT, oral glucose tolerance test; GDM, Gestational Diabetes Mellitus; HOMA-IR, 
Homeostatic Model Assessment for Insulin Resistance; RDS, Respiratory Distress Syndrome.
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distress syndrome, septicaemia, stillbirth, small for gesta-
tional age (<10th, <5th and <3rd) as per population-based 
centile, hypoglycaemia, hypocalcaemia, Apgar at 10 min, 
birth trauma such as shoulder dystocia fracture and 
hyperbilirubinaemia.
Cord blood will be collected and tested for c-peptide 
levels in the neonate. In addition, cost data and health-re-
lated quality of life (HRQL) measures will be captured. 
Cost data include the cost of myo-inositol and placebo 
administration, cost of routine tests, additional laboratory 
tests and other investigations in both groups, cost of clinic 
visits, hospital admissions, type of delivery, cost to treat 
adverse events (AEs), antenatal costs, postnatal costs and 
neonatal costs. Being a pilot trial, a sample size of 200 is 
adequate to assess feasibility outcomes but inadequate to 
show a difference in clinical outcomes between groups. 
However, we will be collecting these outcomes in this pilot 
trial to inform the future definitive full-scale trial on the 
feasibility of collecting and assessing these outcomes in 
our population groups.
A schedule of assessments is shown below in table 1.
Qualitative evaluation
The qualitative evaluation will explore the acceptability of 
the trial and the intervention among participating women 
and healthcare professionals. This will be achieved 
through direct observation of recruitment and semistruc-
tured interviews as outlined below.
Recruitment observation
A sample of recruitment appointments (approximately 
3–4 participants at each site) will be observed in order 
to gain detailed knowledge of women’s specific needs or 
concerns, as well as factors in the recruitment setting/
environment that may impact on the recruitment process 
and outcomes.
Brief interview/open-ended questionnaire with those who decline 
recruitment
Women who decline to participate in the pilot trial will be 
invited to complete an open-ended questionnaire (either 
verbally or in writing) on: (1) their reasons for declining 
to participate and (2) their feedback on the recruitment 
process. Responses will inform recruitment procedures 
both for the pilot trial and the potential future full-scale 
trial. This model has been recently used in a pilot trial of 
group antenatal care at Barts Health NHS Trust (Preg-
nancy Circles study) and was found to work well as a 
means of identifying barriers to trial participation.9
Interviews with randomised participants
Following consent, semistructured interviews will be 
conducted with a purposive sample of approximately 
15–20 women at different points in the trial. Interviews 
will be conducted approximately 2 months after randomi-
sation (20–24 weeks of pregnancy) and towards the end 
of pregnancy (36–38 weeks) to capture women’s experi-
ences throughout pregnancy.
The first interview will explore participants’ experience 
of their pregnancy so far, their understanding, beliefs 
and perception of gestational diabetes, perceived accept-
ability of the study procedures and intervention and 
other factors that can influence adherence. The second 
phase of interviews will purposively include 10 partici-
pants from the first interview phase who found interven-
tion compliance and adherence particularly difficult or 
easy in the early stages of the study. This will be to address 
any further difficulties and supports for managing adher-
ence to the intervention and any further experiences 
with study participation, data collection methods and 
follow-up procedures. We will also endeavour to interview 
a sample of women who drop out of the trial.
Table 1 This table shows the schedule of assessments for the EMmY study
Visit number 0 1 2 3 4 5
Gestational weeks <16 weeks
12–
15+6 weeks ~20 weeks ~28 weeks ~36 weeks Delivery
Tasks 
  Consent x
  Participant demographic data x
  OGTT/HbA1c prerandomisation (if 
previous GDM history)
x
  Randomisation x
  Delivery of intervention x x x x
  OGTT to diagnose GDM x
  Assess adherence (app/diary) x x x x
  Maternal, fetal and neonatal outcomes x
  Qualitative data collection (interviews) x x
*Assessments will be completed as near to the scheduled date as possible, depending on participant’s appointment date.
OGTT, oral glucose tolerance test.
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All interviews will be audio-recorded with consent, and 
participants will also be offered a £10 voucher for each 
interview.
Interviews and/or focus groups with healthcare professionals
Semistructured interviews or focus groups will be 
conducted with a cross-section of key healthcare profes-
sionals (approximately 10–15 consisting of obstetricians, 
diabetologists and midwives) who are involved in deliv-
ering the intervention, and/or who have expertise in the 
area of gestational diabetes. Here, we will explore various 
approaches to managing/preventing GDM in multiethnic 
populations in the NHS setting. We will obtain their views 
on barriers to recruitment, compliance, retention and any 
suggestions on how these could be overcome. Informed 
consent will be gained, and a prepared interview guide 
will include questions arranged in topics.
Patient and public involvement
Prior to the grant application, the development of the 
EMmY research question was informed by patients’ prior-
ities and preferences. In our survey of pregnant women 
(n=71) within the Barts Health NHS Foundation Trust, 
83% (59/71) agreed that there was a need to prevent 
gestational diabetes. More women indicated that they 
would be inclined to take myo-inositol (79%, 56/71) than 
follow a complex lifestyle intervention (60%, 43/71), 
and 8 out of 10 informed that they may or would defi-
nitely join a trial on myo-inositol. Additionally, two-thirds 
of healthcare professionals surveyed (66%, 58/88) were 
keen to participate in a trial on myo-inositol.
We have collaborated with ‘Katie’s Team’, a women’s 
health and childbirth-specific patient and public involve-
ment advisory group10 to inform several elements of the 
EMmY pilot trial. Katie’s Team members contributed 
to the development of the study design, reviewed the 
trial documents such as the PISs and informed consent 
forms (ICFs) and developed the interview schedule. 
Patients and public representatives are not involved in 
recruitment or the conduct of the study.
We will submit study findings for publication in 
published in peer-reviewed journals. Study results will be 
circulated to participants, healthcare professionals and 
members of Katie’s Team through newsletters, who in 
turn will further disseminate through traditional means 
and social media platforms.
Data analysis
Statistical analysis
Data will be analysed using descriptive statistics in order 
to inform trial feasibility and process. Given that this is 
a pilot study, the sample size is not adequately powered 
to assess the effect of the intervention on outcomes. 
However, where appropriate, we will present point esti-
mates of effect sizes (eg, mean differences and relative 
risks) and associated 95% CIs. The primary analysis will 
also involve the estimation of the proportions of the 
primary outcomes (ie, eligible women recruited into the 
trial, recruited women who complete the trial and adhere 
to the intervention treatment until delivery). We will also 
test if the proportions of the primary outcomes differ 
between the treatment group and the control group. We 
will explore the effect of mother’s ethnicity, history of 
previous gestational diabetes and maternity unit attended 
on recruitment, adherence and attrition. All analysis will 
be performed using Stata software (StataCorp. 2015. Stata 
Statistical Software: Release V.14).
Economic analysis
A cost–utility analysis will be undertaken using a short-
term time horizon (the ‘within trial’ period) to obtain 
preliminary estimates of the cost-effectiveness of myo-ino-
sitol supplementation versus placebo in the prevention 
of gestational diabetes, which will inform the full-scale 
trial. The cost utility measures in the short run will be the 
incremental cost per unit of change per QALY gained. 
Unit costs will be collected and assessed from the perspec-
tive of the NHS and personal social services via standard 
sources. QALYs will be calculated based on the HRQL 
collected during the trial from the EQ-5D-5L question-
naires. The QALYs experienced from baseline to end of 
trial will be calculated as the area underneath this profile. 
Cost–utility will be calculated as the mean cost difference 
between the intervention and control group divided by 
the mean difference in outcomes to give the incremental 
cost-effectiveness ratio. Cost-effectiveness acceptability 
curves will be constructed, and we will subject the results 
to extensive deterministic sensitivity analysis.
Qualitative data analysis
Interview data will be subjected to thematic analysis. Tran-
scripts will be coded for themes and concepts relating 
to women's and health professionals’ experiences and 
perceptions of this intervention and the study. In this 
way, we will develop an analytical framework to identify 
key themes and how these inter-relate. Where possible, 
we will use constant comparison techniques and examine 
deviant cases to refine our analysis.
Clinical management
Besides myo-inositol and placebo, EMmY does not involve 
any other intervention. All aspects of antenatal care will 
be at the discretion of local clinicians. Further manage-
ment of women diagnosed with gestational diabetes will 
be as per local guidelines for management of gestational 
diabetes.
Participant withdrawal
After consent, a participant can decide to self-withdraw 
from the trial. Clear distinctions will be made if the partic-
ipant is only withdrawing from the trial but allowing 
further follow-up or withdrawing from both the trial and 
follow-up. A participant can also be withdrawn from the 
trial treatment if based on the opinion of the clinical 
carers and the investigators, it is medically necessary to 
do so. However, with any postrandomisation exclusions, 
the research team will endeavour to obtain and record 
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the reasons for withdrawal and any AEs in the case report 
form (CRF). Where appropriate, efforts will be made to 
follow-up women who withdraw for all safety and efficacy 
outcomes.
If a participant explicitly withdraws consent to any 
further data collection, her decision will be respected, 
noted in the final study form and no further data will 
be collected from that participant. The participant will 
continue with NHS standard practice for follow-up care.
Data management
All participants in the EMmY trial will be given a unique 
trial number and will be identified to their local sites by 
their NHS hospital number. The chief investigator has 
a responsibility to ensure that participant anonymity 
is protected, maintained and associated participant 
information kept confidential and managed in accor-
dance with the Data Protection Act (1998-UK), the 
sponsor’s data management standard operating proce-
dures (SOPs), The Research Governance Framework for 
Health and Social Care, The Research Ethics Committee 
Approval and the NHS Caldicott Guardian. All data will 
be monitored centrally and locally at the trials coor-
dinating centre—Barts Research Centre for Women’s 
Health (BARC) for consistency, viability and quality using 
bespoke data management systems.
All participants’ data obtained for the trial, including 
personal information, will be anonymised, held securely 
and treated as strictly confidential. The data will be entered 
onto a secure computer database, either by a member of 
the research team or directly via a secure internet connec-
tion. All staff at each participating site and at the trials 
unit share a responsibility of care to prevent unauthorised 
disclosure of personal information. No identifiable indi-
vidual data will be published. In accordance to the MRC 
guidelines on data retention, participants’ collected data 
will be kept for 20 years following the end of trial to allow 
for verification and further data sharing via an individual 
patient data meta-analysis for instance.
Monitoring and auditing
The study sites will perform remote trial monitoring 
according to the agreed trial monitoring plan and self-mon-
itoring template at the trials coordinating centre—BARC. 
Trial monitoring will include source data verification, 
checks on all ICFs and eligibility for randomisation log and 
a sample set of CRFs. Any major discrepancies with respect 
to trial regulatory matters and study protocol found at a site 
visit will trigger an audit of trial data by the coordinating 
team at the site involved, independently of the sponsor and 
investigators. The chief investigator will ensure that the trial 
is conducted in compliance with the principles of the Decla-
ration of Helsinki (1996) and in accordance with all appli-
cable regulatory requirements including, but not limited to, 
the Trust and Research Office policies and procedures, the 
Research Governance Framework, guidelines for good clin-
ical practice and any subsequent amendments. Any form of 
non-compliance will be captured through communications 
and updates, monitoring visits, CRFs and other sources. 
In order to identify and verify any developing trends, the 
sponsor will maintain a log of any non-compliances, assess 
them and action a timeframe in which they need to be dealt 
with. In the event of any safety information that may require 
significant changes to the risk/benefit analysis of the study, 
the protocol, the ICF and the PIS will be amended and 
submitted to Research Ethics Committee (REC) for revi-
sion and approval. All participants of the EMmY study will 
be duly informed and provided with a revised copy of the 
PIS and the ICF to confirm their wish to continue where 
possible.
Sample handling, labelling and logging
Participants’ samples collected will be processed by either 
NHS laboratory services, or by Affinity Biomarker Labs 
(Imperial College London). Samples will be labelled 
with the date of collection and participant’s unique trial 
number. On arrival at the laboratories, samples will be 
handled as per routine clinical practice and local poli-
cies. Samples will be stored, processed and analysed by 
laboratory staff as defined by study SOPs, with any incon-
sistencies referred back to the research team or the clin-
ical team. All samples received and processed in the NHS 
labs will be logged onto the NHS database, and samples 
received and processed by the Affinity Biomarker Labs 
will be logged onto the trial specific secure database.
Trial organisation
EMmY has a Project Steering Committee (PSC) that 
provides independent supervision of the trial, providing 
advice to the chief and coinvestigators and the sponsor on 
all aspects of the trial and affording protection for patients 
by ensuring the trial is conducted according to the princi-
ples of GCP in clinical trials. The trial will also be overseen 
by a Trial Management Group (TMG), who will meet regu-
larly up until the end of the trial to evaluate trial progress 
and resolve any potential challenges. The TMG consists of 
the lead investigators, research midwives, and the project 
team at BARC.
EMmY is a pilot study with a low risk intervention and 
therefore no major safety concerns. In addition, EMmY 
aims to primarily assess the feasibility of conducting a 
potential full-scale trial rather than the effectiveness of 
the intervention and therefore does not require a data 
monitoring committee.
Safety assessment
Adverse events, are defined as any untoward medical 
occurrences in a participant that are not necessarily 
related to the intervention administered. AEs will be 
recorded by the PI in the CRF and the participant’s 
medical notes. Participants experiencing AEs will be 
followed up by the research team. Serious adverse events 
(SAEs) are defined as any untoward occurrences that 
results in death, that is life threatening, requires hospi-
talisation or prolongation of existing hospitalisation, that 
results in persistent or significant disability or incapacity 
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or is otherwise considered medically significant by the PI. 
Any SAEs will be reported to the sponsor within 24 hours 
of learning of the event and to the main REC within 15 
days in line with the required timeframe.11
Indemnity
EMmY is sponsored by Queen Mary University of London 
(QMUL) as defined by the Research Governance Frame-
work for Health and Social Care (April 2005). EMmY is 
also covered by the insurance brokers of QMUL on a ‘No 
Faults Compensation for Clinical Trials and/or Human 
Volunteer Studies’. This policy covers or indemnifies the 
insured in respect of their legal liabilities arising out of 
the insured’s activities.
Ethics and dissemination
EMmY has received site-specific approval for each partic-
ipating site. EMmY is also registered online at  ISRCTN. 
com (ISRCTN48872100). The chief investigator will 
coordinate dissemination of data from this study. The 
results from the trial will be submitted for publication in 
a major journal. The PSC will be responsible for approval 
of the main manuscript prior to submission for publica-
tion. Authorship of presentations and reports related to 
the study will be in the name of the lead investigators. 
Publications will name local coordinators as well as 
those involved in central coordination and trial manage-
ment. The writing will be the responsibility of a writing 
committee including all of the investigators.
DISCUSSION
Approximately 40% of all women who are diagnosed 
with gestational diabetes progress to type 2 diabetes 
within 5 years postdelivery, in addition to their increased 
risk of gestational diabetes in future pregnancies.12 13 
Infants born to mothers with gestational diabetes are at 
an increased risk of impaired glucose regulation, obesity 
and diabetes, leading to a vicious cycle of accumulated 
risks in the next generation.14 15 Therefore, preventing 
gestational diabetes provides intergenerational benefits, 
preventing chronic diseases in both mothers and their 
offspring.
With a projected increase in the NHS yearly spend 
(from £8.8 billion to £13 billion) on type 2 diabetes and 
its complications,16 preventing gestational diabetes has 
significant societal and economic benefits. However, 
evidence on effective and acceptable approaches to 
preventing gestational diabetes is lacking.17 Randomised 
trials on lifestyle changes has shown no significant differ-
ence in the incidence of gestational diabetes between 
groups.6 18 Women have reported on the difficulty of 
incorporating exercise into their daily routine as a result 
of child care, pregnancy symptoms and work commit-
ments.17 Trials on the use of metformin in preventing 
the incidence of gestational diabetes also reported on 
no statistically significant difference between groups.18 
There is therefore a need for a simple, effective, safe and 
acceptable intervention in preventing the onset of gesta-
tional diabetes in high-risk pregnant women.
Myo-inositol is a dietary nutritional supplement, which 
is present in staple foods such as meat and legumes, and 
is currently sold over the counter as a food supplement. 
Its use is not contraindicated in pregnancy.19 20 Existing 
trials have shown the potential benefits of periconceptual 
myo-inositol supplementation in preventing folate resis-
tant neural tube defects. The dose and timing of myo-ino-
sitol supplementation specified within the study are based 
on the need to ensure completion of fetal organogenesis 
by 12 weeks of gestation, reducing any theoretical risk 
to the fetus.21 Myo-inositol supplementation until the 
end of pregnancy also has a resulting effect on reducing 
macrosomia.22
Preliminary evidence on the effects of myo-inositol in 
pregnancy, based on small trials, suggests a reduction in 
gestational diabetes by up to 60%.6
To examine whether myo-inositol supplementation 
prevents the incidence of gestational diabetes in high-
risk women, a large sample size will be required costing 
approximately £1.7 million. Prior to undertaking a large-
scale trial on the effects of myo-inositol, there is a need 
to pilot trial procedures, assess our ability to recruit 
and randomise women in a timely fashion and evaluate 
their adherence to study protocol and attrition rates. 
Evaluating adherence is vital to understanding women’s 
perception of the intervention and the trial, as well as 
trial elements that may impact on their acceptability and 
hence retention in the trial.23 This may include women’s 
understanding of gestational diabetes, their percep-
tion of risk, their attitudes towards a screening test for 
early pre-gestational diabetes and possible side effects of 
myo-inositol. It is important to explore potential variability 
across sites in the management of women at risk of gesta-
tional diabetes and subsequently women with a diagnosis 
of gestational diabetes. The knowledge of these factors 
can inform recruitment and intervention delivery strate-
gies within the full-scale trial, allowing for the adaptation 
of trial processes to its local context being more sensitive 
to the needs of participants.24
CONCLUSION
The EMmY pilot trial is to inform a large definitive 
randomised controlled trial on the effects of myo-inositol 
supplementation on preventing the incidence of gesta-
tional diabetes and further complications in pregnant 
women at risk of developing gestational diabetes.
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